Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to six new employees, totaling 64,050 shares at an exercise price of $30.30, equivalent to the closing price on February 8, 2022. Additionally, 2,025 restricted stock units were awarded. These grants were made under the Company’s 2020 Inducement Plan, approved in January 2020, complying with NYSE regulations. Founded in 2015, Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies.

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted options to purchase 38,850 shares and restricted stock units for 925 shares to six new employees. The exercise price is set at $31.75, equivalent to the closing price on January 24, 2022. The equity awards comply with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus Biosciences is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to two new employees totaling 41,800 shares at an exercise price of $37.56, the closing price on January 10, 2022. This issuance is in accordance with the Company’s 2020 Inducement Plan, approved under NYSE rules. Founded in 2015, Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies targeting various cancer pathways.

Arcus Biosciences (NYSE:RCUS) updates on its clinical programs, detailing six molecules targeting cancer pathways. In 2022, it anticipates multiple data presentations, including results from ARC-7 and ARC-8 studies. Despite initial data from the ARC-4 study showing no significant differentiation in clinical activity for etrumadenant, ongoing efforts continue in other studies. Arcus expects its cash position to nearly double to $1.4 billion following option payments from Gilead, enhancing funding for future clinical trials.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to four new employees totaling 23,400 shares at an exercise price of $44.59, the closing price on December 23, 2021. This grant is part of the Company’s 2020 Inducement Plan, approved by the Board of Directors in January 2020. The company focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting various biological pathways.

Gilead Sciences (GILD) and Arcus Biosciences (RCUS) confirmed the closure of Gilead's option exercises on three of Arcus’ clinical-stage programs, including domvanalimab, AB308, etrumadenant, and quemliclustat, as of November 17, 2021. This transaction, following the expiration of antitrust waiting periods, entitles Arcus to receive $725 million from Gilead. Future collaboration includes co-development and profit-sharing in the U.S., along with tiered royalties on international sales. The collaboration supports advancements in cancer treatment through innovative drug candidates.

Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced the closing of Gilead's option exercises for three clinical-stage programs in Arcus's portfolio, including anti-TIGIT molecules and other candidates. This agreement results in option payments of $725 million from Gilead to Arcus, expected in early Q1 2022. Under the collaboration, Gilead and Arcus will co-develop the programs and share costs, with Gilead holding exclusive commercialization rights outside the U.S. The transaction followed the expiration of the Hart-Scott-Rodino waiting period.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options to eight new employees, allowing them to purchase a total of 83,400 shares at $44.17 each, reflecting the closing price on December 8, 2021. This issuance is part of the 2020 Inducement Plan approved in January 2020 under the NYSE rule for inducements. Arcus focuses on developing innovative cancer therapies and has initiated six investigational medicines targeting key biological pathways.

Arcus Biosciences (NYSE:RCUS) and Taiho Pharmaceutical announced the exercise of Taiho's option for the anti-TIGIT antibodies, domvanalimab and AB308, in Japan and parts of Asia. This follows a prior agreement from September 2017. Taiho will make an upfront payment and additional milestone payments. Domvanalimab is in Phase 2 and Phase 3 trials for non-small cell lung cancer, while AB308 is in a Phase 1b trial for various malignancies. The collaboration aims to enhance the development and commercialization of these therapies.